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Background: Depression and anxiety are highly prevalent and represent a significant and well described public
health burden. Whilst first line psychological treatments are effective for nearly half of attenders, there remain a
substantial number of patients who do not benefit. The main objective of the present project is to establish an
infrastructure platform for the identification of factors that predict lack of response to psychological treatment for
depression and anxiety, in order to better target treatments as well as to support translational and experimental
medicine research in mood and anxiety disorders.
Methods/design: Predicting outcome following psychological therapy in IAPT (PROMPT) is a naturalistic
observational project that began patient recruitment in January 2014. The project is currently taking place in
Southwark Psychological Therapies Service, an Improving Access to Psychological Therapies (IAPT) service currently
provided by the South London and Maudsley NHS Foundation Trust (SLaM). However, the aim is to roll-out the
project across other IAPT services. Participants are approached before beginning treatment and offered a baseline
interview whilst they are waiting for therapy to begin. This allows us to test for relationships between predictor
variables and patient outcome measures. At the baseline interview, participants complete a diagnostic interview; are
asked to give blood and hair samples for relevant biomarkers, and complete psychological and social questionnaire
measures. Participants then complete their psychological therapy as offered by Southwark Psychological Therapies
Service. Response to psychological therapy will be measured using standard IAPT outcome data, which are routinely
collected at each appointment.
Discussion: This project addresses a need to understand treatment response rates in primary care psychological
therapy services for those with depression and/or anxiety. Measurement of a range of predictor variables allows for
the detection of bio-psycho-social factors which may be relevant for treatment outcome. This will enable future
clinical decision making to be based on the individual needs of the patient in an evidence-based manner.
Moreover, the identification of individuals who fail to improve following therapy delivered by IAPT services could
be utilised for the development of novel interventions.Background
Depression and anxiety within the general population
are a continuing and significant public health problem
[1]. The Adult Psychiatric Morbidity Survey showed that
16% of adults overall met the criteria for at least one
common mental health disorder (defined in this survey* Correspondence: nina.grant@kcl.ac.uk
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from depression and/or anxiety has a significant impact
on an individual’s life, including increased mortality [3],
reduced quality of life [4] and reduced attendance and
productivity at work [5]. The Improving Access to Psy-
chological Therapies (IAPT) service was developed to
provide psychological treatment for people with these
common mental health disorders in order to address the
high prevalence and burden of these disorders, and the
problem that many people are untreated.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mended as first-line treatment for mild to moderate depres-
sion and anxiety, in some cases along with appropriate
medication, by the National Institute for Clinical Excellence
[6]. IAPT services use a standardised protocol and col-
lect considerable amounts of outcome data. This pro-
vides an opportunity for researchers to collect data on
large populations (3000 per year in some services) of
people with common mental health disorders undergo-
ing similar treatments. Recently, the IAPT programme
has reported early successes over its first three years,
notably the treatment of “the first million patients” [7].
Overall recovery rates, defined as moving from caseness
to non-caseness on measures of low mood and anxiety,
were 45% in the last quarter of 2011/12, demonstrating
consistent improvement over the duration of the
programme and progression towards the original target
of 50% [7].
Whilst these recovery rates are encouraging, they also
show that around half of patients are not meeting stand-
ard definitions of recovery at the end of their treatments.
Further, it is likely that a substantial proportion of those
who do recover then go on to relapse in due course.
Our knowledge of predictors of treatment response for
depression and anxiety, both in terms of psychological
and pharmacological treatments, is limited. It is likely
that depression and anxiety disorders have many and
varied causes, across psychological, social, and biological
factors. Only by studying large cohorts of patients re-
ceiving treatments will it be possible to identify factors
that predict positive or negative response and, by under-
standing these, develop new targets for treatment.
The aim of this project is therefore to provide an in-
frastructure to understand the predictors of treatment
response, and to allow recruitment and follow up of
subgroups of participants who do not respond to treat-
ment in order to devise experimental studies to identify
new treatments (both psychological and pharmacological).
The project is supported by the SLaM Biomedical Re-
search Centre which aims to provide infrastructure sup-
port for experimental medicine studies, and phase 1 and 2
trials.
Project objectives
The objectives of the project are to:
1. Explore and describe the population attending for
psychological therapy in one South London IAPT
service (Southwark)
2. Embed data collection procedures within SLaM
IAPT services to facilitate future research
programmes
3. Collect biological samples to establish predictors of
response to psychological therapy4. Establish longitudinal predictors of response to
psychological therapy
5. Identify participants for further, associated studies
under the PROMPT theme
Methods/design
Design
This project uses a naturalistic, observational design. All
eligible patients referred to Southwark Psychological
Therapies Service are initially asked to consent to be
contacted for research purposes, and those that agree
are approached to take part in the project. Patients are
approached before beginning therapy to allow collection
of baseline measures and will then continue their treat-
ment as usual within the IAPT service.
The project team carried out consultation with service
users in the design of relevant materials. Firstly, the
Southwark IAPT Service User Forum was consulted in
two meetings about the procedure and suggested mate-
rials to be used in the project. Secondly, the FAST-R ser-
vice (Feasibility and Support to Timely recruitment to
Research) provided feedback and comments about the
participant information sheet and consent forms used in
this project.
Ethical approval
The project has been approved by Bromley NHS Research
Ethics Committee on 21st October 2013 (reference: 13/
LO/1347).
Participants
Participants are recruited from one IAPT service pro-
vided by South London and Maudsley NHS Foundation
Trust (SLaM). Inclusion criteria for this project are that
patients are accepted by the IAPT service for treatment,
and that they are able to give informed consent. Patients
are excluded if they are not sufficiently fluent in English.
Sample size
This is a naturalistic, observational project and therefore
our sample size estimates are based on patient through-
put and human resources. Based on these factors, we es-
timate to recruit up to 600 patients at baseline in the
first year of the project. Using existing drop-out rates
from SLaM IAPT services, we expect a drop-out rate of
approximately 28%, leaving us with a sample of 472. Ac-
cording to power calculations, with power set at 0.8 and
alpha at 0.05, this will allow us to detect standardised ef-
fect sizes of 0.13 in linear regression models estimating
the effects of baseline factors in recovery. This is consid-
ered to be clinically significant; for example, a recent
study of predictors of recovery [8] in the same setting
showed that baseline PHQ-9 and GAD-7 scores were
Table 1 Demographic and treatment factors
Demographics
Socio-economic status Current medication
Ethnicity Physical health
Age Benefits status
Working status Marital status
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tiple regression model, with effect sizes ranging 0.14-
0.21.
Procedure
All data are collected at a baseline research visit, prior to
the patients starting treatment in the service. These
visits take place at the NIHR/Wellcome Trust King’s
Clinical Research Facility. This visit involves a diagnostic
interview carried out with a trained researcher, collec-
tion of biological samples (hair and blood), and comple-
tion of a range of questionnaires. Outcome measures
will be collected in everyday contact with IAPT staff as
part of routine IAPT practice at each treatment session
and will be available on the IAPT patient record system.
These variables are described below.
Measures
Predictor variables
The final choice of clinical and psychological predictors
was based on discussions over a series of meetings with
a large multidisciplinary group of academic experts, a
systematic review of the literature conducted by the pro-
ject coordinator (NG) and discussion over 3 subsequent
meetings with the core Steering Committee who are all
co-authors of this paper. The final list, which was
reached by group consensus, has been considered com-
prehensive while at the same time manageable within a
target completion time of 90 minutes for the whole as-
sessment. This was judged to be the maximum time that
we could impose on participants. Pilot work with the
interview has confirmed that this is a realistic estimate
of the time needed for completion.
PROMPT is collecting biological data as part of the
National Institute for Health Research (NIHR) BioRe-
source for Mental Health, which aims to enrol and col-
lect biological samples from 52,000 healthy volunteers,
patients and relatives. For PROMPT, this includes blood
processed for DNA, RNA, buffy coat, serum and plasma.
This sampling protocol allows for testing of an extensive
battery of biomarkers relevant to treatment response in
psychiatric disorders, and which are being routinely
tested in a number of ongoing studies on a range of
diagnostic categories. The BioResource project has sep-
arate ethical approval for the collection, storage and ana-
lysis of biological samples.
Demographic and patient characteristics are shown in
Table 1. Table 2 shows the predictor variables, which
will be collected at the baseline interview.
Diagnosis
The Mini International Neuropsychiatric Interview (MINI)
is used to assess diagnosis of participants in this project.
The MINI is a structured interview which assesses DSMdiagnoses, and is rapid to administer. The MINI covers
the following diagnoses: Major Depressive Episode (MDE);
recurrent MDE; MDE with melancholic features; dys-
thymia; suicidality; mania and hypomania; panic dis-
order; social phobia; agoraphobia; obsessive compulsive
disorder; post traumatic stress disorder; alcohol abuse;
alcohol dependence; substance use; substance depend-
ence; psychotic disorders; mood disorder with psychotic
features; anorexia; bulimia; generalised anxiety disorder;
and antisocial personality disorder. The MINI has good
internal reliability and consistency [9].Personality disorder
All participants complete the Standardised Assessment of
Personality – Abbreviated Scale (SAPAS) [10], an eight
item screen for personality disorder. Each item is rated as
yes or no, giving a maximum score of eight. In clinical pop-
ulations, a cut-off three is suggested for identification of
cases at high risk of personality disorder. The SAPAS has
acceptable internal consistency (Cronbach’s alpha = 0.68).
Participants will also complete the borderline personality
subsection of the Structured Clinical Interview for DSM-IV
Personality Disorders (SCID-II; [11]). The SCID-II is a
semi-structured interview delivered by a trained member of
the research team to assess presence of anti-social personal-
ity disorder and borderline personality disorder. Questions
are rated as 1 “absent”, 2 “sub-threshold” or 3 “threshold”.
The SCID-II demonstrated acceptable test-retest reliability
(kappa = 0.68) as well as acceptable inter-rater reliability
(kappa = 0.68) in previous studies.Hypomanic symptoms
The Hypomania Checklist (HCL-16) is used to screen
for the presence of hypomanic symptoms to aid in the
diagnosis of bipolar disorders [12]. The HCL-16 has
been developed from the original HCL-32 and studies
have supported the reliability and validity of this shorter
measure [12]. Each item is rated as either “yes, present
or typical of me” or “no, not present or not typical of
me”. There is support for a two factor structure for this
scale, the first a ‘active-elated’ factor and the second a
‘risk-taking/irritable’ factor. Reliability for these two sub-
scales and the total score are within acceptable levels
(Cronbach’s alphas 0.65-0.77).
Table 2 Predictor variables
Predictors Measure Reference
Biological sampling Blood, saliva, hair N/A
Diagnosis MINI [9]
Personality disorder SAPAS [10]
SCID-II [11]
Hypomania Hypomania Checklist [12]
Previous treatments and psychiatric history Maudsley Staging Model [13]
Social support Oslo 3 Social Support Scale [14]
Self-criticism Forms of Self Criticising and Self Reassuring Scale (FSCRS) [15]
Stressful life events List of Threatening Experiences [16]
Childhood abuse Childhood Trauma Questionnaire [17]
Quality of life EQ-5D [18]
Illness perceptions Brief Illness Perceptions Questionnaire [19]
Self-efficacy General Self-efficacy Scale [20]
Alcohol AUDIT [21]
Drug use Drug abuse/dependence subscale - PDSQ [22]
Grant et al. BMC Psychiatry 2014, 14:170 Page 4 of 8
http://www.biomedcentral.com/1471-244X/14/170Previous treatments
Information will be collected about the number of previ-
ous episodes each patient has experienced, duration of
previous episodes, their previous history of psychological
or pharmacological treatment and the age of onset.
Current prescribed medication will also be recorded, in-
cluding type of drug, number of doses per day and dos-
age. Treatment resistance will be quantified using a
modified version of the Maudsley Staging Model [13].Social support
Social support is measured using the three-item Oslo
Social Support scale (OSS-3) [14]. The first question
measures how many people the participant is close to,
with response options ranging from none to more than
five. The second question asks the participant to rate
how much of an interest other people take in the partici-
pant’s life. The third question asks participants to rate if
they could get practical help from their neighbours, with
responses ranging from very easy to very difficult.Self-critical thoughts
Participants complete the Forms of Self-critical/Attack-
ing and Self-reassuring Scale (FSCRS) [15]. This is a 23-
item measure eliciting a score for self critical thinking
and self-reassuring thoughts. The self-critical subscale is
divided in to hated self, inadequate self, and reassured
self. Items are rated using a Likert scale ranging from 0
“not at all like me” to 4 “extremely like me”. The three
subscales have good internal consistency with Cronbach’s
alphas of 0.86-0.90 [15]. A recent study has supported the
three factor structure of this scale [23].Life events
Stressful life events are assessed using the List of Threat-
ening Events Questionnaire [16], a 12-item measure which
includes negative events such as serious illness, death, un-
employment and loss of an important relationship. Partici-
pants mark whether the event has happened to them, and
if it has, the date that it occurred. The scale has good test-
retest reliability for most items (kappa = 0.78 – 1.0) with
the exception of the question relating to having an item
stolen, which has lower reliability (kappa = 0.24). There is
also good agreement between individual participants and
others (kappa = 0.7 - 0.9) and good agreement with inter-
view based measures (sensitivity = 89%, specificity = 74%).
Childhood trauma
Traumatic events during childhood are measured using
the Childhood Trauma Questionnaire, a 28-item meas-
ure that covers five domains. These are: emotional
abuse, physical abuse, sexual abuse, emotional neglect,
and physical neglect. Questions include “people in my
family hit me so hard that it left bruises or marks” (emo-
tional abuse). Each item is rated on a five point Likert
scale from “never true” to “very often true”, with scores
for each sub scale ranging from 5-25, and the total score
from 25-125. The subscales have good internal consistency
with Cronbach’s alphas ranging from 0.61 – 0.92) [17].
Quality of life
Quality of life is measured using the EuroQol (EQ-5D)
[18] which consists of a five part questionnaire and one
visual analogue rating scale. The five questions cover
self-care, pain, mood, mobility and usual activities and
are answered on a three-point Likert scale, ranging from
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scale asks participants to indicate how they would rate
their health overall today, on a scale from 0 “worst
health imaginable” to 100 “best health imaginable”.
Illness perceptions
Beliefs about illness are assessed using the nine-item
Brief Illness Perceptions Questionnaire [19]. Five ques-
tions assess cognitive representations of illness, two as-
sess emotional representations and one assesses illness
comprehension. These questions are rated from 0 to 10.
The final question asks respondents to list three factors
they consider had a causal role in their illness. The ori-
ginal questionnaire contains the term “illness” but this
has been changed to “depression/anxiety” for the current
project.
Self-efficacy
Self-efficacy is measured using the General Self-efficacy
Scale [20]. This is a ten item measure which is rated
from 1 “not at all” to 4 “exactly true” and is designed to
assess respondents beliefs in their ability to complete
tasks. The scale has been shown to have good reliability
across a variety of participant groups (Cronbach’s alpha
ranging from 0.76-0.90).
Alcohol
Alcohol consumption is assessed using the 10-item Al-
cohol Use Disorders Identification Test (AUDIT). The
questions in this scale measure alcohol consumption, de-
pendence and problems related to alcohol use. For ex-
ample, questions include “How often during the last year
have you failed to do something that was expected of
you because of drinking?” Items have different response
categories but each are scored from 0 – 4, giving a pos-
sible range of 0 – 40. A score of above eight is indicative
of a problem with drinking [21]. A review paper includ-
ing 18 studies using the AUDIT reported that internal
consistency is reliably reported to be above 0.80 [24].
Drug use
Drug use is assessed using the drug use/dependency
subscale of the Patient Diagnostic Screening Question-
naire [22]. This is a six item measure with response op-
tions of yes or no. Questions include “(during the past
two weeks) did you think you had a drug problem?”.
Outcome measures
The primary outcome for PROMPT will be symptom
change for depression and anxiety, as measured nation-
ally by IAPT using by the PHQ-9 (Patient Health Ques-
tionnaire) and GAD-7 (Generalised Anxiety Disorder
assessment) [25,26]. The PHQ-9 is a self-administered
scale covering nine symptoms of depression, which arerated from 0 “not at all” to 3 “nearly every day”. With a
sample of patients from primary care, the scale was
found to have good reliability (Cronbach’s alpha = 0.89)
and sensitivity and specificity of 88% [25]. The GAD-7 is
a seven item self report measure, rated from 0 “not at
all” to 3 “nearly every day”. The scale has good reliability
(Cronbach’s alpha = 0.92) and sensitivity of 89% and spe-
cificity of 82% [26].
Both these measures are routinely collected as part of
standard IAPT practice at every treatment session. Data
will be gathered from the IAPT patient records system
(IAPTus) with prior consent of participants. A score of
10 or more on the PHQ-9, and a score of 8 or more on
the GAD-7 indicates caseness [25,26]. Participants who
score above these thresholds for caseness on both the
PHQ-9 and GAD-7 at their final appointment, will be
defined as being in the ‘non-recovered’ group. The
standard IAPT measure of Reliable Change Index will
also be used as an outcome measure of treatment re-
sponse which will be based on a drop of 6 points for the
PHQ-9 and a drop of 5 points for the GAD-7 [27].
Secondary outcomes will be employment status, bene-
fits status, engagement with services, and work and
social functioning. Employment and benefits data is rou-
tinely collected at each IAPT appointment and entered
on to the patient records system. Measures of engage-
ment with IAPT services will include failure to engage,
drop-out or discharge. Work and social functioning is
measured using the Work and Social Adjustment Scale,
a five item self-report measure collected as part of the
routine IAPT outcome measures. This information will
be collected from the care pathway of the patient re-
cords system IAPTus, which is routinely updated by
IAPT clinical and admin staff.
Analysis
Descriptive summaries of socio-demographic inform-
ation will be provided for baseline, and follow up
time-points for the sample as appropriate. Descriptive
summaries at the level of IAPT services will also be pro-
vided. Missing data will be reported for all treatment
time-points to describe retention/drop-out rates. Rea-
sons for drop-out will be recorded. We will use the
STROBE statement (http://www.strobe-statement.org/
index.php?id = available-checklists) for a list of items to
be reported. All statistical analyses will be carried out in
the statistical software package STATA. Descriptive sum-
maries for all outcome measures will be provided. Con-
tinuous outcome measures will be inspected visually to
assess the normality of data and to check for outliers.
Univariate associations with IAPT non-recovery will be
explored using t-tests (for normally distributed data) and
Mann-Whitney tests (for skewed data). The independ-
ence of associations between the proposed predictor
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linear mixed model methods (for continuous outcome
measures) and logistic regression (for categorically-
defined outcomes i.e. recovered vs. non-recovered). The
possibility of sex interactions and non-linear effects will
be examined. Analysis of residuals from the model will
be performed to assess the model fit and to check for
outliers.
Discussion
The project outlined in this paper aims to identify factors
that predict response to psychological therapy in a pri-
mary care setting. Psychological therapy for depression
and anxiety is currently recommended as a first-line ther-
apy by clinical guidelines [6], yet is currently only available
to 10-15% of sufferers [7]. Better targeted services are
needed as access is unlikely to increase significantly and it
is also currently uncertain to what degree the new Clinical
Commissioning Groups will fund IAPT schemes. Out-
come data currently available suggest that over half of pa-
tients are not meeting nationally recognised recovery rates
[8]. At present there have been no other large-scale, natur-
alistic studies investigating predictors of outcome in an
IAPT setting. The IAPT setting is particularly applicable
to research, as patients are required to complete standard
measures of mood and functioning at each contact. This
project aims to embed recruitment practices in to an
IAPT service allowing further studies to be carried out in
the future. A secondary aim of this project is be extend
the research to other IAPT sites.
Participants will complete therapy in a real world clin-
ical setting allowing collection of meaningful observa-
tional data. Participants will be interviewed before
beginning treatment, thus allowing collection of baseline
data which can be used to predict future treatment out-
come. Because of the nature of the outcome measure-
ment in IAPT, participants will not need to attend for a
second research interview as this information can be
collected from the IAPT electronic patient records sys-
tem. The numbers of patients attending for psycho-
logical treatment at IAPT services has been steadily
increasing, such that, this is now the commonest route
of talking therapy for mild to moderately affected people.
A large scale research study investigating predictors of
treatment response in this setting is therefore essential.
Collecting data from participants in a naturalistic set-
ting, whilst providing ecologically valid data, is not
without its limitations. We can anticipate around 30%
drop-out of patients during IAPT therapy, meaning that
we will lose some final outcome data for many patients
we see at baseline. However, as data is collected on
every contact, with a national completion rate of 90%,
this will be minimised as we will be able to use data
from the final session attended. This also affords us theopportunity to investigate if there are common factors
that may explain drop-out. IAPT therapy is not standar-
dised and this will introduce variability within our
sample. Patients may receive one-to-one cognitive be-
havioural therapy with a trained CBT therapist, or a
clinical psychologist. They may also receive guided
self-help with a psychological well-being practitioner. Fur-
ther, patients may attend for group therapy or psycho-
educational workshops. Increasingly, IAPT services are
offering alternatives to CBT including but not limited to;
interpersonal psychotherapy, couples therapy, and eye
movement desensitization and reprocessing therapy.
IAPT services are accessed by a wide variety of patients,
with a diverse range of presenting complaints. The pro-
ject will initially focus its recruitment on one borough
(Southwark) whose services are currently provided by
South London and Maudsley NHS Foundation Trust. In
terms of ethnic diversity, the Office for National Statistics
reported that the population of Southwark comprises
62% from White groups, 27% from Black groups and 11%
from other groups. There will also be variety in use of
prescribed medication amongst the participants, and this
information is not always routinely collected within IAPT
services. To overcome this, participants will be asked
about their prescribed medication at the research inter-
view. However, it will not be possible to monitor any
changes in dosage or medication when looking at out-
comes following treatment. As part of the standard IAPT
data collection, participants are asked if they are pre-
scribed medication, and if they are currently taking their
medication. It is possible that a participant may change
dose or even drug whilst receiving therapy.
Whilst one of the strengths of this project is its natural-
istic nature, this also presents some challenges in terms of
the analysis of outcome data. In large scale randomised
controlled trials that compare efficacy of different therap-
ies, or medication vs therapy, manualised therapy is often
used. Therapists in such studies will be supervised more
closely than in standard practice, will be less free to vary
sessions and will have their skills monitored. This project
will involve therapists from different backgrounds includ-
ing but not limited to; trained CBT therapists; clinical psy-
chologists with IAPT high intensity therapy training and
psychological well-being practitioners both pre- and post-
qualification. These therapists will also have different
amounts of experience and bring their own styles and
ways of working to their patients. All of this will contrib-
ute to the variance in non-specific therapeutic factors in-
fluencing outcomes. At this point, we have not identified
an efficient way of measuring these important ‘therapist
factors’ but we will be working with team leaders in order
to capture this in future research.
It is possible that patients who agree to take part in
the project may not be representative of the IAPT
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pants who do not consent to take part in the main re-
search program so it will be possible to compare
participants with non-participants on standard factors
such as demographics and initial PHQ-9 and GAD-7
scores. However, it is possible that other factors may
prevent some people from agreeing to take part in the
research such as health literacy, previous experience of
psychological therapy and employment status. Due to
the variability both in the participants, the therapists
and also the therapy offered, the project will rely on a
large sample size to detect clinically significant effects.
Conclusions
PROMPT aims to identify predictors of non-response
to first line psychological treatment provided by at an
IAPT service within a diverse population of South
London. The aim is to translate findings into improved
treatment outcomes, better patient care and more effi-
cient services within IAPT, and to support ongoing re-
search into the causes and effective treatment of IAPT
non-responders.
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